Poor adherence with medication therapy has been estimated to be responsible for more than 5 percent of all hospital admissions, with an associated direct cost exceeding $8 billion. This is a particular problem with drugs that have a narrow therapeutic index. Warfarin is such a drug. If used correctly, warfarin is highly efficacious in preventing thromboembolism (TE) in patients with conditions that put them at risk. However, errors in its use can lead to life-threatening thromboembolic and bleeding complications. In addition, errors can lead to increased medical costs, reduced quality of life, patient dissatisfaction, and discontinuation of a highly efficacious therapy. Because of the numerous conditions that put patients at risk, warfarin is the tenth most commonly prescribed medication in the United States. As a result of this widespread use and the drug?s narrow therapeutic index, warfarin errors are extremely common. Despite our medical knowledge and attendant attempts to control many factors that can affect anticoagulation levels, proper anticoagulation is extremely difficult to maintain. Even in optimal clinical settings, about one-half of all patient time is spent either under-or over-anticoagulated. In our hospital, complications from warfarin are the most commonly reported adverse drug reaction and warfarin is the leading cause of admissions for serious adverse drug events. Even """"""""near misses"""""""" can lead to increased medical costs and discontinuation of an otherwise extremely effective therapy. Poor patient adherence with warfarin therapy is often cited as one of the most common errors with the drug. However, the problem with adherence has not been addressed, and no study has rigorously attempted to identify predictors of poor adherence with warfarin. Therefore, the purpose of this study is to determine the human and system factors (both patient and medical practice specific) that lead to errors with warfarin, specifically focusing on adherence.
The aims are to perform a prospective cohort study of anticoagulation patients to determine the specific clinical, demographic, health care structural, pill-taking practices, and psychosocial factors associated with poor adherence, and to develop a predictive index that can identify patients at risk for medication errors. The hypothesis is that specific clinical and demographic characteristics, psychosocial factors (e.g., poor cognition, passive coping strategies) and variables describing medical practice (e.g., time providers spend with patients, primary care physician support) and medication-taking practices (e.g., reminder systems) will predict poor adherence with warfarin. The ultimate goal of this research is to provide a more complete understanding of the epidemiology of patients' errors.

Agency
National Institute of Health (NIH)
Institute
Agency for Healthcare Research and Quality (AHRQ)
Type
Research Program Projects (P01)
Project #
1P01HS011530-01
Application #
6546849
Study Section
Special Emphasis Panel (ZHS1)
Project Start
2001-09-07
Project End
2006-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hennessy, S; Leonard, C E; Localio, A R et al. (2011) Prescriber adherence to pharmacokinetic monitoring service recommendations for aminoglycoside dosing and the risk of acute kidney injury. Int J Clin Pharmacol Ther 49:536-44
Cruess, Dean G; Localio, A Russell; Platt, Alec B et al. (2010) Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med 17:33-42
Kim, Michelle M; Metlay, Joshua; Cohen, Abigail et al. (2010) Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults. Pharmacoepidemiol Drug Saf 19:731-6
Platt, Alec B; Localio, A Russell; Brensinger, Colleen M et al. (2010) Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Chest 137:883-9
Hennessy, Sean; Leonard, Charles E; Freeman, Cristin P et al. (2009) CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol 49:1483-7
Haynes, Kevin; Hennessy, Sean; Localio, A Russell et al. (2009) Increased risk of digoxin toxicity following hospitalization. Pharmacoepidemiol Drug Saf 18:28-35
Koppel, Ross; Wetterneck, Tosha; Telles, Joel Leon et al. (2008) Workarounds to barcode medication administration systems: their occurrences, causes, and threats to patient safety. J Am Med Inform Assoc 15:408-23
Metlay, Joshua P; Hennessy, Sean; Localio, A Russell et al. (2008) Patient reported receipt of medication instructions for warfarin is associated with reduced risk of serious bleeding events. J Gen Intern Med 23:1589-94
Platt, Alec B; Localio, A Russell; Brensinger, Colleen M et al. (2008) Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf 17:853-60
Volpp, Kevin G; Loewenstein, George; Troxel, Andrea B et al. (2008) A test of financial incentives to improve warfarin adherence. BMC Health Serv Res 8:272

Showing the most recent 10 out of 14 publications